|Home > South Asia >
Natco Pharma to challenge grant of EMR to Novartis
Mumbai: Natco Pharma Ltd is planning to challenge the grant of exclusive marketing rights (EMR) to Swiss drug maker Novartis for its anti - cancer drug Glivec. Natco Pharma informed Bombay Stock Exchange that the company in January 2003 has already launched Veenat Imatinib Mesylate for treatment of Chronic Myeloid Leukemia (CML). Natco is also examining various other legal options available to oppose the EMR Grant to Novaritis.
|© Copyright 2002-2003 AFAR|